



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Product Information

<b>Description:</b>	This anti-CD96 antibody is a purified, recombinant monoclonal antibody that recognizes human CD96. This antibody has been tested for neutralization of CD96 interaction with CD155 in a binding assay.
<b>Background:</b>	CD96, also known as Tactile (T cell activation, increased late expression), is an immune checkpoint receptor of the immunoglobulin superfamily of proteins found in T and NK cells. Other proteins of the same superfamily include CD226 (also known as DNAM-1) and TIGIT (T cell immunoglobulin and ITM domain), with CD96 and TIGIT acting as inhibitory receptors and CD226 as a co-stimulatory receptor. CD96 binds to CD155, competing with CD226. CD96 plays a role in NK-cell adhesion to target cells, inhibiting NK cell cytokine release. It also plays an inhibitory role in Th9 cells and is a cancer stem cell marker. An imbalance in CD155/CD96 and CD155/CD226 can lead to lack of or to excessive immune responses. In LUAD (lung adenocarcinoma) the levels of CD96 in CD8 <sup>+</sup> T cells are elevated compared to healthy individuals, possibly promoting a hypo-immune response. CD96, together with TIGIT, has become a widely researched target in immunotherapy, and blockage of CD96 binding to CD155 combined with other therapies, such as anti-PD-1 (programmed death protein 1) or doxorubicin chemotherapy, has shown great promise. The development of strategies to block CD96 inhibitory immune responses will continue to be an active area of research, opening new avenues of treatment for cancer patients.
<b>Species:</b>	Human
<b>Isotype:</b>	IgG1
<b>Clonality:</b>	Monoclonal
<b>Concentration:</b>	1.89 mg/ml
<b>Expression System:</b>	HEK293
<b>Purity:</b>	≥90%
<b>Format:</b>	Aqueous buffer solution.
<b>Formulated In:</b>	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
<b>MW:</b>	Heavy Chain: 49 kDa + glycans; Light Chain: 23 kDa
<b>Glycosylation:</b>	This antibody runs at a higher MW by SDS-PAGE due to glycosylation.
<b>Stability:</b>	At least 12 months at -80°C.
<b>Storage:</b>	-80°C
<b>Instructions for Use:</b>	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
<b>Assay Conditions:</b>	The neutralizing activity of Anti-CD96 Neutralizing Antibody (BPS Bioscience #102141) was measured using CD155:CD96[Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit (BPS Bioscience #82532)
<b>Applications:</b>	Useful for studying the binding and neutralization of CD96 in ELISA and in cellular assays.

## Quality Control Data

### 4-20% SDS-PAGE Coomassie Staining



### CD155:CD96[Biotinylated] Neutralization Assay

